Ruizhi Zheng1, Dan Zhou2, Yimin Zhu1. 1. Department of Epidemiology & Biostatistics, School of Public Health, Zhejiang University, Hangzhou, China. 2. Department of pathophysiology, School of Medicine, Zhejiang University, Hangzhou, China.
Abstract
BACKGROUND: Metabolically healthy obese phenotype (MHO) refers to obese individuals with absence of metabolic abnormalities such as dyslipidaemia, insulin resistance and hypertension. Many studies reported the long-term prognosis of MHO on diseases and mortality with inconsistent results. METHODS: We performed a meta-analysis to assess the risks of cardiovascular (CV) events and all-cause mortality for MHO individuals. Original prospective observational studies were searched in Medline, EMBASE, Web of Science and Cochrane library up to 30 September 2015. In this meta-analysis, the relative risk (RR) calculated on the basis of the incident number of disease events and deaths in participants and the corresponding multivariable-adjusted HR were both extracted to calculate pooled risk estimates. A random-effects model was used if there was heterogeneity among studies; otherwise, the fixed-effects model was used. RESULTS: 22 prospective studies, involving 584 799 participants, were archived in the analyses. With metabolically healthy normal weight as the reference, the MHO phenotype was associated with a higher risk of CV events (RR 1.50, 95% CI 1.27 to 1.77; HR 1.60, 95% CI 1.38 to 1.84). However, MHO individuals were not associated with increased risk of all-cause mortality (RR 1.18, 95% CI 0.83 to 1.66; HR 1.07, 95% CI 0.92 to 1.25). CONCLUSIONS: The meta-analysis confirms a positive association between a metabolically healthy obese phenotype and the risk of CV events. However, higher risk for all-cause mortality is not evident in metabolically healthy obese individuals. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Metabolically healthy obese phenotype (MHO) refers to obese individuals with absence of metabolic abnormalities such as dyslipidaemia, insulin resistance and hypertension. Many studies reported the long-term prognosis of MHO on diseases and mortality with inconsistent results. METHODS: We performed a meta-analysis to assess the risks of cardiovascular (CV) events and all-cause mortality for MHO individuals. Original prospective observational studies were searched in Medline, EMBASE, Web of Science and Cochrane library up to 30 September 2015. In this meta-analysis, the relative risk (RR) calculated on the basis of the incident number of disease events and deaths in participants and the corresponding multivariable-adjusted HR were both extracted to calculate pooled risk estimates. A random-effects model was used if there was heterogeneity among studies; otherwise, the fixed-effects model was used. RESULTS: 22 prospective studies, involving 584 799 participants, were archived in the analyses. With metabolically healthy normal weight as the reference, the MHO phenotype was associated with a higher risk of CV events (RR 1.50, 95% CI 1.27 to 1.77; HR 1.60, 95% CI 1.38 to 1.84). However, MHO individuals were not associated with increased risk of all-cause mortality (RR 1.18, 95% CI 0.83 to 1.66; HR 1.07, 95% CI 0.92 to 1.25). CONCLUSIONS: The meta-analysis confirms a positive association between a metabolically healthy obese phenotype and the risk of CV events. However, higher risk for all-cause mortality is not evident in metabolically healthy obese individuals. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
Epidemiology of cardiovascular disease; META ANALYSIS; OBESITY
Authors: Yong-Moon Mark Park; Alexandra J White; Hazel B Nichols; Katie M O'Brien; Clarice R Weinberg; Dale P Sandler Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: Morgana Mongraw-Chaffin; Meredith C Foster; Cheryl A M Anderson; Gregory L Burke; Nowreen Haq; Rita R Kalyani; Pamela Ouyang; Christopher T Sibley; Russell Tracy; Mark Woodward; Dhananjay Vaidya Journal: J Am Coll Cardiol Date: 2018-05-01 Impact factor: 24.094
Authors: Camille Lassale; Ioanna Tzoulaki; Karel G M Moons; Michael Sweeting; Jolanda Boer; Laura Johnson; José María Huerta; Claudia Agnoli; Heinz Freisling; Elisabete Weiderpass; Patrik Wennberg; Daphne L van der A; Larraitz Arriola; Vassiliki Benetou; Heiner Boeing; Fabrice Bonnet; Sandra M Colorado-Yohar; Gunnar Engström; Anne K Eriksen; Pietro Ferrari; Sara Grioni; Matthias Johansson; Rudolf Kaaks; Michail Katsoulis; Verena Katzke; Timothy J Key; Giuseppe Matullo; Olle Melander; Elena Molina-Portillo; Concepción Moreno-Iribas; Margareta Norberg; Kim Overvad; Salvatore Panico; J Ramón Quirós; Calogero Saieva; Guri Skeie; Annika Steffen; Magdalena Stepien; Anne Tjønneland; Antonia Trichopoulou; Rosario Tumino; Yvonne T van der Schouw; W M Monique Verschuren; Claudia Langenberg; Emanuele Di Angelantonio; Elio Riboli; Nicholas J Wareham; John Danesh; Adam S Butterworth Journal: Eur Heart J Date: 2018-02-01 Impact factor: 29.983